Han Bo, Woodell-May Jennifer, Ponticiello Michael, Yang Zhi, Nimni Marcel
Department of Surgery, University of Southern California, 1840 North Soto Street EDM-191, Los Angeles, CA 90032, USA.
J Bone Joint Surg Am. 2009 Jun;91(6):1459-70. doi: 10.2106/JBJS.H.00246.
Demineralized bone matrix is an osteoinductive and osteoconductive material that is often used in orthopaedic surgery to induce bone formation. Autologous platelet-rich plasma, which contains proliferative and chemoattractant growth factors, has been used as a demineralized bone matrix adjuvant with mixed results. One variable during clinical use appears to be whether the platelet-rich plasma is activated with thrombin or is implanted in a liquid form with intact platelets. The objective of the present study was to determine if platelet-rich plasma can increase the osteoinductivity of demineralized bone matrix when used without thrombin activation.
The bioactivity of the demineralized bone matrix was evaluated in vitro by determining alkaline phosphatase production by C2C12 myoblast cells. The effect of thrombin activation on platelet-rich plasma was studied in vitro by evaluating osteosarcoma and bone marrow stromal cells for cell number and transforming growth factor-beta1 activation. Demineralized bone matrices supplemented with platelet-rich plasma, with or without thrombin activation, were implanted intramuscularly in athymic rats and were examined at fourteen, twenty-eight, and fifty-six days. Histological samples were analyzed for osteogenesis and chondrogenesis. Osteogenesis was further characterized on the basis of alkaline phosphatase activity.
In vitro, thrombin triggered an immediate release of growth factors from the platelet-rich plasma, and the platelet-rich plasma increased the number of both osteosarcoma and stromal cells in a dose-dependent manner. Thrombin activation of the platelet-rich plasma eliminated such stimulatory effects. In vivo, the platelet-rich plasma stimulated chondrogenesis on Day 14 and osteogenesis on Days 28 and 56, whereas thrombin-activated platelet-rich plasma acted as an inhibitor of such events. In addition, inflammatory cells were detected in demineralized bone matrix samples that were mixed with thrombin-activated platelet-rich plasma. These cells were not present in matrix mixed with platelet-rich plasma alone.
Platelet-rich plasma significantly increased in vivo demineralized bone matrix osteoinductivity only when used without thrombin activation.
脱矿骨基质是一种具有骨诱导性和骨传导性的材料,常用于骨科手术中诱导骨形成。富含自体血小板的血浆含有增殖性和趋化性生长因子,已被用作脱矿骨基质佐剂,但结果不一。临床使用过程中的一个变量似乎是富含血小板的血浆是用凝血酶激活还是以完整血小板的液体形式植入。本研究的目的是确定未用凝血酶激活的富含血小板的血浆是否能增加脱矿骨基质的骨诱导性。
通过测定C2C12成肌细胞产生碱性磷酸酶的情况,在体外评估脱矿骨基质的生物活性。通过评估骨肉瘤和骨髓基质细胞的细胞数量及转化生长因子-β1的激活情况,在体外研究凝血酶激活对富含血小板血浆的影响。将添加了富含血小板血浆(有或无凝血酶激活)的脱矿骨基质肌肉内植入无胸腺大鼠体内,并在第14、28和56天进行检查。对组织学样本进行骨生成和软骨生成分析。根据碱性磷酸酶活性进一步表征骨生成情况。
在体外,凝血酶触发了富含血小板血浆中生长因子的立即释放,且富含血小板的血浆以剂量依赖方式增加了骨肉瘤和基质细胞的数量。富含血小板血浆的凝血酶激活消除了这种刺激作用。在体内,富含血小板的血浆在第14天刺激软骨生成,在第28天和56天刺激骨生成,而凝血酶激活的富含血小板血浆则是这些事件的抑制剂。此外,在与凝血酶激活的富含血小板血浆混合的脱矿骨基质样本中检测到炎症细胞。单独与富含血小板血浆混合的基质中不存在这些细胞。
仅在未用凝血酶激活时,富含血小板的血浆才能显著提高体内脱矿骨基质的骨诱导性。